{"created":"2023-05-15T16:29:55.185435+00:00","id":855,"links":{},"metadata":{"_buckets":{"deposit":"1f54b6fc-fbb2-45fa-a10f-04b21acaab60"},"_deposit":{"created_by":2,"id":"855","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"855"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00000855","sets":["29:30:1713167819629:108"]},"author_link":["4040","4048","4038","4045","4041","4049","4047","4035","4046","4050","4044","4039","4037","4043","4036","4042"],"item_3_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-06","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"7","bibliographicPageStart":"1","bibliographicVolumeNumber":"64","bibliographic_titles":[{"bibliographic_title":"Acta medica Nagasakiensia"}]}]},"item_3_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Aim: This study compared the efficacy and safety of Bmab+oral 5-Fluorourasil (Bmab+o-5-FU) including Bmab+Capecitabine (Cape) with that of intensive chemotherapy including L-OHP or CPT-11 for patients with metastatic colorectal cancer (mCRC).\nMethods: Between January 2006 and February 2017, 40 elderly (?70 years) chemotherapy-naive patients with mCRC (male/female=22/18; median age, 76.0 years) were retrospectively reviewed. The treatment regimens were Bmab+o-5-FU (n=19)and intensive regimens (n=21). Intensive regimens comprised 17 L-OHP and 4 CPT-11 doublet chemotherapies.\nResults: The median progression-free survival (PFS) with Bmab+o-5-FU and intensive regimens was 281 and 215 days, respectively. The median survival time with Bmab+o-5-FU and intensive regimens was 961 and 1,002 days, respectively. No significant differences were observed in the overall survival or PFS between Bmab+o-5-FU and the other regimens. The disease control rate was 94.7% with Bmab+o-5-FU and 81.0% with intensive regimens. The rate of grade ?3 hematologicaladverse events was 5.3% for Bmab+o-5-FU and 15.8% for intensive regimens.\nConclusions: With its similar survival benefit to intensive regimens, high disease control rate and good feasibility, Bmab+o-5-FU seems a fine treatment choice for elderly mCRC patients.","subitem_description_type":"Abstract"}]},"item_3_description_64":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Acta medica Nagasakiensia, 64(1), pp.1-7; 2020","subitem_description_type":"Other"}]},"item_3_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Nagasaki University School of Medicine"}]},"item_3_source_id_10":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA00508430","subitem_source_identifier_type":"NCID"}]},"item_3_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00016055","subitem_source_identifier_type":"ISSN"}]},"item_3_text_62":{"attribute_name":"sortkey","attribute_value_mlt":[{"subitem_text_value":"01"}]},"item_3_text_63":{"attribute_name":"出版者別言語","attribute_value_mlt":[{"subitem_text_value":"長崎大学医学部"}]},"item_3_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kobayashi, Kazuma"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tetsuo, Hanako"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yamaguchi, Shun"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ito, Shinichiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Torashima, Yasuhiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Inoue, Yusuke"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Okada, Satomi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Enjoji, Takahiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kuba, Sayaka"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kosaka, Taiichiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Adachi, Tomohiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hidaka, Masaaki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yamanouchi, Kosho"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kanetaka, Kengo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Takatsuki, Mitsuhisa"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Eguchi, Susumu"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-18"}],"displaytype":"detail","filename":"ActMed64_1.pdf","filesize":[{"value":"830.1 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ActMed64_1.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/855/files/ActMed64_1.pdf"},"version_id":"24c84fd1-013f-47f0-bc91-557d1e7d20f4"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"elderly patient","subitem_subject_scheme":"Other"},{"subitem_subject":"colorectal cancer","subitem_subject_scheme":"Other"},{"subitem_subject":"bevacizumab","subitem_subject_scheme":"Other"},{"subitem_subject":"o-5-FU","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Bevacizumab +oral 5-fluorourasil versus intensive chemotherapy for the treatment of elderly patients with metastatic colorectal cancer","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Bevacizumab +oral 5-fluorourasil versus intensive chemotherapy for the treatment of elderly patients with metastatic colorectal cancer"}]},"item_type_id":"3","owner":"2","path":["108"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-06-17"},"publish_date":"2020-06-17","publish_status":"0","recid":"855","relation_version_is_last":true,"title":["Bevacizumab +oral 5-fluorourasil versus intensive chemotherapy for the treatment of elderly patients with metastatic colorectal cancer"],"weko_creator_id":"2","weko_shared_id":2},"updated":"2024-04-15T08:02:30.535369+00:00"}